Market Update (NASDAQ:REGN): Regeneron Reports Fourth Quarter and Full Year 2015 Financial and Operating Results

[PR Newswire] – TARRYTOWN, N.Y., Feb. 9, 2016 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) today announced financial results for the fourth quarter and full year 2015 and provided an update on development … Read more on this. Regeneron Pharmaceuticals, Inc. (REGN) , with a current market cap of $40.47B, opened at $357.00. Looking at today’s market, REGN one day range is $325.00 to $387.97 with a trailing 52-week range being $325.00 to $605.93. REGN shares are currently priced at 31.07x this year’s forecasted earnings, which makes them relatively expensive compared to the industry ’s -3.68x forward p/e ratio. In a review of the consensus earnings estimate this quarter, 19 sell-side analysts are looking at $3.36 per share, which would be $0.57 better than the year-ago quarter and a $0.05 sequential decrease. The full-year EPS estimate is $12.57 which would be a $2.57 improvement than last year’s full-year earnings. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $1.17 Billion. If realized, that would be a 45.83% increase over the year-ago quarter. Recently, Canaccord Genuity downgraded REGN from Buy to Hold (Jan 27, 2016). Previously, Chardan Capital Markets downgraded REGN from Neutral to Sell. The average price target for REGN shares by the analysts covering it is $587.90, which is 64.68% above where the stock opened. See more in (NASDAQ:REGN) Similar Articles: Company Update: Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – Sanofi and Regeneron Announce New Praluent® (alirocumab) Injection Analyses Presented at AHA Scientific Sessions 2015 Company Update (NASDAQ:REGN): Regeneron Reports Third Quarter 2015 Financial and Operating Results Stock Update: Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – Regeneron and Sanofi Announce New Positive Praluent® (alirocumab) Phase 3 Data Presented at ESC Congress 2015